Consumer safety notice Home About Hikma Our strategy Quickfinder About Hikma Hikma factsheet Our mission & vision Our values Our strategy Our strengths Our history Our businesses Our management Our partners Corporate governance Keep yourself updated about Hikma Stay informed Our vision The goals we have set for ourselves. What Hikma is striving to achieve in the long-run. Read about Hikma’s vision Our mission Our mission is the anchor point of our daily operations. These are the values we live up to. Read about Hikma’s mission Our strategy Our performance this year reflects the excellent results achieved by our Injectables business in the US, the strength of our businesses in MENA and a solid performance in Europe. It also demonstrates the strength of our unique business model and our focus on the strategic priorities we have identified for future growth. We made good progress delivering our strategy this year. We have continued to strengthen our competitive position and gain share in our key markets, develop our global portfolio of higher value, more differentiated products, expand our manufacturing capacity and drive greater operational efficiencies. Strengthening our leading position in the MENA region Since our IPO in 2005, we have made eight acquisitions in MENA. We have invested over $200 million in capex, expanded our geographic reach, strengthened our manufacturing capabilities, developed our product portfolio and grown our sales teams. Through these investments we have built a very strong position in the MENA region. In 2012, we successfully leveraged these investments and our position as the leading regional pharmaceutical manufacturer to drive revenue growth in the MENA of over 20%. Our performance was strongest in markets such as Egypt and Algeria, where recent investment to expand manufacturing capacity has enhanced our ability to meet the growing demand for our products. This strong performance was achieved despite the challenges we are facing in many of our MENA markets as competition increases, political and social issues cause disruptions and costs increase due to higher inflation. By continuing to invest in our facilities, optimise our product portfolios and improve operational efficiency, we have been able to build stronger market positions across all our MENA markets. We remain very positive about the outlook for our businesses in MENA. We have a long track record of operating successfully in this region, despite the economic and geopolitical challenges and we see excellent opportunities to grow our MENA revenue and profitability over the medium and long-term. Developing our global product range The development of our global product portfolio, particularly the continuous introduction of new, higher value products, is a key strategic focus across the group. To achieve this, we have continued to invest in R&D. We are also broadening our sources of new products beyond our own in-house capabilities to include alliances with external partners and product acquisitions. In 2012, we continued to grow our portfolio through the launch of 14 new products and 17 new dosage forms and strengths across the group and 77 total launches across all countries. In our MENA markets, we continue to deliver strong sales growth from our leading portfolio of anti-infective products, whilst developing our cardiovascular, diabetes, central nervous system (“CNS”), oncology and respiratory portfolios. Our strategy is to continue bringing new branded generics to market as well as innovative, patented products under license from our growing number of global partners. Acquisitions also contribute to the growth in our product portfolio and can bring new in-license relationships and additional therapeutic categories. In 2012, we launched 47 oral and 15 injectable products across our MENA markets. In the US, we are continuing to deliver a steady stream of new ANDAs, with four oral and eight injectable approvals in 2012. We are successfully introducing higher value, more differentiated products to our portfolio including products such as argatroban, iron gluconate, phenylephrine and testosterone – all excellent products with strong market positions. In Europe, we launched 10 products during 2012. Extending our reach and diversity through partnerships Since Hikma’s inception, partnerships have been an integral part of our strategy for developing a portfolio of differentiated, innovative and high quality products for sale across the group. Contact us Stay informed Site map Terms and conditions Disclaimer Privacy policy Cookies policy © Hikma Pharmaceuticals PLC 2014